Name: Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection (Video) | JoVE Journal
Uploaded: 2020-06-08T12:30:00.000+00:00
Duration: 7 min 35 s
Description: Learn a non-invasive stool DNA method to detect colorectal neoplastic lesions using the FL-DNA kit with qPCR analysis. This approach enhances screening accuracy when combined with existing tests for better patient outcomes.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

The authors have no acknowledgments.

Patients were recruited at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) of Meldola (FC, Italy) between 2013 and 2015. Enrolled patients were into protocol IRSTB002, approved by the Ethics Committee of IRST - IRCCS AVR (25/10/2012, ver. 1). All methods were performed in accordance with relevant guidelines and regulations. Written informed consent was obtained from all patients.
1. DNA extraction from stool
<ol>
	<li>Use a kit to prepare stool samples (see Table of Materials). Select and treat the fecal material by performing the extraction according to the manufacturer’s instructions. Amplify the purified DNA directly or store at -20 °C for subsequent analysis.</li>
</ol>
2. Preparation of positive control, standards, spike-in DNA, and clinical samples
<ol>
	<li>Preparation of standards and samples
	<ol>
		<li>To prepare the positive control, standards, spike-in DNA, and all clinical samples, centrifuge an aliquot of positive control, standards, and spike-in DNA, then resuspend each reagent by adding the correct amount of provided water (see below). Then, carefully vortex the positive control, standard, and spike-in DNA, then centrifuge for 10 s. To achieve a complete resuspension of the dry reagents, store the liquid reagents at room temperature (RT) for 30 min before use.
		<ol>
			<li>The positive control is human DNA in a dry format. Resuspend each aliquot with 750 µL of water.</li>
			<li>The spike-in DNA is salmon (Oncorhynchus keta) DNA, which is used as an exogenous internal control to verify the possible presence of inhibitors in DNA samples extracted from stool. Resuspend each aliquot with 100 µL of water.</li>
		</ol>
		</li>
		<li>To prepare the standard curve, produce four 1:5 dilutions starting from the stock solution. The standard points must be 10 ng/reaction, 2 ng/reaction, 0.4 ng/reaction, and 0.08 ng/reaction.</li>
	</ol>
	</li>
	<li>Preparation of the 1x spike-in DNA
	<ol>
		<li>Prepare the spike-in DNA control directly before use.</li>
		<li>Prepare the 1x spike-in DNA control by mixing 5 µL of FL-DNa spike with 20 µL of sterile water. The number of 1x spike-in DNA control samples will be prepared according to the number of the samples to be analyzed, plus the positive control.</li>
	</ol>
	</li>
	<li>Preparation of samples
	<ol>
		<li>Mix 75 µL of the samples (clinical samples or positive control) with 25 µL of 1x spike-in DNA, yielding a total volume of 100 µL.</li>
	</ol>
	</li>
</ol>
3. Amplification and determination of the FL-DNA value using qPCR Easy PGX
NOTE: Complete amplification mixtures containing specific primers and probes targeting the human DNA and the internal control are provided in a lyophilised format in 8 well strips for FL-DNA Mix A and FL-DNA Mix B. Standards, positive and negative controls, and samples must be amplified with both lyophilized mixes. Clinical samples only must only be amplified in duplicate with both lyophilized mixes.
<ol>
	<li>See the Table of Materials for qPCR instrument and operating software.
	<ol>
		<li>Open the operating software and set up the plate and thermal profile:
		<ol>
			<li>Set up the plate as shown in Table 1.
			<ol>
				<li>Set the well type for all eight positions in column 1 as Standard.</li>
				<li>Set the well type for the A2 and B2 wells as NTC.</li>
				<li>Set the well type for C2 and D2 (the positive controls) as Unknown.</li>
				<li>Set the well type for all other positions as Unknown.</li>
				<li>Select all 96 positions, and add the Dyes FAM and HEX. Click Sync Plate.</li>
			</ol>
			</li>
			<li>Set the thermal profile according to Table 2.</li>
		</ol>
		</li>
		<li>Centrifuge the needed number of strips for 10 s to bring the contents to the bottom of the tube.</li>
		<li>Gently remove the seals from the strips, while paying attention to retain the contents, and add to the respective strips: negative control: 20 µL of water; sample: 20 µL of DNA; standard curve: 20 µL of standard 1, 2, 3, or 4; positive control: 20 µL of positive control.</li>
		<li>Close carefully all the strips using the 8 strip flat optical caps and vortex for few seconds.</li>
		<li>Centrifuge the strips for 10 s and load them into the instrument. Then, start the run.</li>
	</ol>
	</li>
</ol>
4. Data analysis
NOTE: Data analysis can be performed automatically or manually depending on the software (see Table of Materials).
<ol>
	<li>At the end of the run, select columns A, C, E, G for "FAM: FL-DNA-A" and "HEX: IC", and columns B, D, F, H for "FAM: FL-DNA-B" and "HEX: IC".</li>
	<li>Set the following for the Standard Quantities Starting Amount: 10 ng/reaction for A1 and B1 wells, 2 ng/reaction for C1 and D1, 0.4 ng/reaction for E1 and F1, and 0.08 ng/reaction for G1 and H1.</li>
	<li>Set Threshold Fluorescence values to 150 for both FAM (FL-DNA A and FL-DNA B) and HEX (IC) channels.</li>
	<li>In the box Result Table, click Column Options | Select All | Ok to obtain the results in both channels with their respective Cq (∆R) and ∆R last values. 
	NOTE: These values are supplied by the Real Time PCR instrument software. ΔR last corresponds to the fluorescence value normalized to the last amplification cycle.</li>
	<li>In the box Result Table, right-click on the table to open the context menu and click Send to Excel to export the raw data.</li>
	<li>Check the values of the standards to verify the suitability of the standard curve.</li>
	<li>For each FL-DNA mix, check the R2 ["R² (∆R)" column] and efficiency ["Efficiency (%)" column] values. If they are in an acceptable range, it is possible to proceed with analysis accordingly to manufacturer’s instructions (Table 3).</li>
	<li>If the results of the FAM channel are not in the expected range, omit one point of the standard curve and reanalyze the run.</li>
	<li>Determine the values of the negative and positive controls with the following formula, considering the "No Cq" values as zero: 
	<img alt="Static equilibrium equation, Q calculation formula for DNA mix quantity, scientific analysis." src="/files/ftp_upload/59426/59426eq1.jpg" data-altupdatedat="1788250015000" data-alt="Equation 1"> 
	<img alt="FL-DNA calculation formula, fluorescence quantification method, molecular analysis equation." src="/files/ftp_upload/59426/59426eq2.jpg" data-altupdatedat="1788250015000" data-alt="Equation 2"></li>
	<li>Compare the obtained values with those reported in Table 4.</li>
	<li>If the reaction controls are in the range of expected values, proceed with analysis of the samples. 
	NOTE: Verify that the Cq values obtained are generated from a real amplification reaction (sigmoidal fluorescence curve) and not from an artifact (linear fluorescence curve).</li>
	<li>To analyze suitability of the sample for each FL-DNA mix, compare the Cq values of the HEX channel. If the value is ≥16, proceed with analysis of the samples. If the value is &lt;16 or there is no Cq, it is likely due to a dispensing error of the FL-DNA Spike. Therefore, it is not possible to analyze the samples.</li>
	<li>Calculate the average of the Cq values in the "HEX" channel of the positive control using the following formula: 
	<img alt="CqHEX calculation formula; average of Cq HEX mix A and Cq HEX mix B; mathematical equation." src="/files/ftp_upload/59426/59426eq3.jpg" data-altupdatedat="1788250015000" data-alt="Equation 3"></li>
	<li>Calculate the average of the Cq values in the "HEX" channel of the sample replicates using the following formula: 
	<img alt="CqHEX sample calculation formula, mathematical expression in experimental analysis context." src="/files/ftp_upload/59426/59426eq4.jpg" data-altupdatedat="1788250015000" data-alt="Equation 4"></li>
	<li>Calculate the ∆CqHEX values according to the following formula: 
	<img alt="Static equilibrium; equation ΔCqHEX = CqHEX_sample - CqHEX_pos; scientific formula." src="/files/ftp_upload/59426/59426eq5.jpg" data-altupdatedat="1788250015000" data-alt="Equation 5"></li>
	<li>Compare the ∆CqHEX values of the samples with those reported in Table 5. </li>
	<li>For each mix (Mix A and Mix B), compare the Cq values of the FAM channel with those reported in Table 6.</li>
	<li>To determine the FL-DNA value of each suitable sample, use the following formula, considering the "No Cq" values as zero: 
	<img alt="Equation illustrating DNA quantification formula Q for comparing replicates in molecular analysis." src="/files/ftp_upload/59426/59426eq6.jpg" data-altupdatedat="1788250015000" data-alt="Equation 6"> 
	<img alt="FL-DNA calculation formula, fluorescence quantification method, molecular analysis equation." src="/files/ftp_upload/59426/59426eq2.jpg" data-altupdatedat="1788250015000" data-alt="Equation 2"> 
	NOTE: Colorectal cancer risk and prevalence is a function of iFOBT and FL-DNA evaluations according to the Fagan nomogram results obtained by Rengucci et al.12 (Table 7).</li>
</ol>

<ol><li>Fearon, E. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Molecular+Genetics+of+Colorectal+Cancer%5BTitle%5D)+AND+%22Annual+Review+of+Pathology%22%5BJournal%5D)">Molecular Genetics of Colorectal Cancer.</a> Annual Review of Pathology. 6, 479-507 (2011).</li>
<li>Sears, C. L., Garrett, W. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Microbes%2C+Microbiota%2C+and+Colon+Cancer%5BTitle%5D)+AND+%22Cell+Host+and+Microbe%22%5BJournal%5D)">Microbes, Microbiota, and Colon Cancer.</a> Cell Host and Microbe. 15, 317-328 (2014).</li>
<li>SEER Stat Fact Sheets: Colon and Rectum Cancer. National Cancer Institute. , Available from: 
 <a target="_blank" href="http://seer.cancer.gov/statfacts/html/colorect.html">http://seer.cancer.gov/statfacts/html/colorect.html</a> (2019).</li>
<li>Levin, B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Screening+and+Surveillance+for+the+Early+Detection+of+Colorectal+Cancer+and+Adenomatous+Polyps%2C+2008%3A+A+Joint+Guideline+From+the+American+Cancer+Society%2C+the+US+Multi-Society+Task+Force+on+Colorectal+Cancer%2C+and+the+American+College+of+Radiology%5BTitle%5D)+AND+%22Gastroenterology%22%5BJournal%5D)">Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline From the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.</a> Gastroenterology. 134, 1570-1595 (2008).</li>
<li>Bosch, L. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Molecular+tests+for+colorectal+cancer+screening%5BTitle%5D)+AND+%22Clinical+Colorectal+Cancer%22%5BJournal%5D)">Molecular tests for colorectal cancer screening.</a> Clinical Colorectal Cancer. 10, 8-23 (2011).</li>
<li>Ahlquist, D. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Molecular+detection+of+colorectal+neoplasia%5BTitle%5D)+AND+%22Gastroenterology%22%5BJournal%5D)">Molecular detection of colorectal neoplasia.</a> Gastroenterology. 138, 2127-2139 (2010).</li>
<li>Calistri, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Fecal+multiple+molecular+tests+to+detect+colorectal+cancer+in+stool%5BTitle%5D)+AND+%22Clinical+Gastroenterology+and+Hepatology%22%5BJournal%5D)">Fecal multiple molecular tests to detect colorectal cancer in stool.</a> Clinical Gastroenterology and Hepatology. 1, 377-383 (2003).</li>
<li>Calistri, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Detection+of+colorectal+cancer+by+a+quantitative+fluorescence+determination+of+DNA+amplification+in+stool%5BTitle%5D)+AND+%22Neoplasia%22%5BJournal%5D)">Detection of colorectal cancer by a quantitative fluorescence determination of DNA amplification in stool.</a> Neoplasia. 6, 536-540 (2004).</li>
<li>Calistri, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Quantitative+fluorescence+determination+of+long-fragment+DNA+in+stool+as+a+marker+for+the+early+detection+of+colorectal+cancer%5BTitle%5D)+AND+%22Cellular+Oncology%22%5BJournal%5D)">Quantitative fluorescence determination of long-fragment DNA in stool as a marker for the early detection of colorectal cancer.</a> Cellular Oncology. 31, 11-17 (2009).</li>
<li>Calistri, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Fecal+DNA+for+noninvasive+diagnosis+of+colorectal+cancer+in+immunochemical+fecal+occult+blood+test-positive+individuals%5BTitle%5D)+AND+%22Cancer+Epidemiology+Biomarkers+and+Prevention%22%5BJournal%5D)">Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individuals.</a> Cancer Epidemiology Biomarkers and Prevention. 19, 2647-2654 (2010).</li>
<li>De Maio, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Circulating+and+stool+nucleic+acid+analysis+for+colorectal+cancer+diagnosis%5BTitle%5D)+AND+%22World+Journal+of+Gastroenterology%22%5BJournal%5D)">Circulating and stool nucleic acid analysis for colorectal cancer diagnosis.</a> World Journal of Gastroenterology. 20, 957-967 (2014).</li>
<li>Rengucci, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Improved+stool+DNA+integrity+method+for+early+colorectal+cancer+diagnosis%5BTitle%5D)+AND+%22Cancer+Epidemiology+Biomarkers+and+Prevention%22%5BJournal%5D)">Improved stool DNA integrity method for early colorectal cancer diagnosis.</a> Cancer Epidemiology Biomarkers and Prevention. 23, 2553-2560 (2014).</li>
</ol>

Maura Menghi is full-time employee of Diatech Pharmacogenetics srl.

Previous studies have demonstrated that DNA integrity analysis of stools extracted by manual and semi-automatic approaches can represent an alternative tool for the early detection of colorectal lesions7,8,9,10,11,12. Molecular, noninvasive screening tests have been developed over the years for the detection of colorectal can...

An erratum was issued for:&#160;<a href="https://www.jove.com/t/59426/evaluation-colorectal-cancer-risk-prevalence-stool-dna-integrity">Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection</a>. An&#160;affiliation&#160;was&#160;updated.
The first&#160;affiliation was updated from:
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)
to:
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

An erratum was issued for:&#160;<a href="https://www.jove.com/t/59426/evaluation-colorectal-cancer-risk-prevalence-stool-dna-integrity">Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection</a>. An&#160;affiliation&#160;was&#160;updated.

Erratum: Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Colorectal cancer (CRC) derives from a multi-step process in which healthy epithelium slowly develops into adenomas or polyps, which progress into malignant carcinomas over time1,2. Despite CRC&#39;s high incidence rate, a downward trend in the percentage of deaths has been observed over the past decade3. Indeed, early diagnostic tools adopted in screening programs have led to early detection and removal of pre-neoplastic adenomas or polyps4. However, due to the different technical limits, none of these methods is optimal. Indeed, in order to improve sensitivity and specificity, many stool DNA tests have been proposed alone or in combination with current routine diagnostic tests5,6.
Typically, healthy mucosa sheds into the fecal stream apoptotic colonocytes, whereas diseased mucosa exfoliates non-apoptotic colonocytes. Fragments of 200 bp or more in length characterize non-apoptotic DNA. This DNA is called long DNA (L-DNA) and has become a utilizable biomarker for CRC early diagnosis. The L-DNA can be isolated from stool specimen and quantified by qPCR using an in vitro diagnostic FL-DNA kit7,8,9,10,11,12.
The test consists of two assays for the detection of FL-DNA fragments ranging from 138 bp to 339 bp. Each assay allows the amplification of FL-DNA (FAM) as well as spike-in DNA (HEX). To ensure optimal amplification of all fragments, the test has been divided into two assays (named &#34;A&#34;&#160;and &#34;B&#34;). The A assay detects two regions of exon 14 of the APC gene (NM_001127511) and a fragment of exon 7 of the TP53 gene (NM_001276760). The B assay detects a fragment of&#160; exon 14 of the APC gene (NM_001127511) and two regions of exons 5 and 8 of the TP53 gene (NM_001276760). The assays do not distinguish between the regions detected. The spike-in DNA corresponds to the Oncorhynchus keta salmon DNA and enables verification that the procedure has been done properly and checks for the possible presence of inhibitors, which may yield false negative results. The FL-DNA concentration is evaluated by absolute quantification using the standard curve method and is expressed as ng/reaction.
The FL-DNA method is a non-invasive and inexpensive stool DNA test that, combined with the immunochemical-based fecal occult blood test (iFOBT), is currently used in CRC screening programs and allows for better predictions of CRC and/or high-risk adenoma lesions12.

<table><tbody><tr><td>1.5 mL and 2 mL polypropylene twist-lock tubes (DNase-, RNase-, DNA-, PCR inhibitor-free)</td><td></td><td></td><td>Consumables required for DNA extraction and Real Time PCR</td></tr><tr><td>Absolute Ethanol (quality of analytical degree)</td><td></td><td></td><td>Reagent required for DNA extraction</td></tr><tr><td>Benchtop centrifuge&amp;nbsp;</td><td></td><td></td><td>Maximum speed of 20000 x g. Instrument required for DNA extraction</td></tr><tr><td>EasyPGX analysis software version 2.0.0</td><td>Diatech Pharmacogenetics</td><td>RT800-SW</td><td>Analysis software&amp;nbsp;</td></tr><tr><td>EasyPGX centrifuge/vortex 8-well strips</td><td>Diatech Pharmacogenetics</td><td>RT803</td><td>Instrument recommended for the Real Time PCR assay</td></tr><tr><td>EasyPGX qPCR instrument 96&amp;nbsp;</td><td>Diatech Pharmacogenetics</td><td>RT800-96</td><td>Instrument recommended for the Real Time PCR assay</td></tr><tr><td>EasyPGX ready FL-DNA</td><td>Diatech Pharmacogenetics</td><td>RT029</td><td>Kit required for the Real Time PCR assay</td></tr><tr><td>Micropipettes (volumes from 1 to 1.000 &amp;micro;L)</td><td></td><td></td><td>Consumables required for DNA extraction and Real Time PCR</td></tr><tr><td>Powder-free disposable gloves</td><td></td><td></td><td>Consumables required for DNA extraction and Real Time PCR</td></tr><tr><td>QIAamp Fast DNA Stool</td><td>Qiagen</td><td>51604</td><td>Kit recommended for the DNA extraction and purification from stool</td></tr><tr><td>Sterile filter tips DNase-, RNase-free (volumes from 1 to 1.000 &amp;micro;L)</td><td></td><td></td><td>Consumables required for DNA extraction and Real Time PCR</td></tr><tr><td>Thermal block e.g. EasyPGX dry block</td><td>Diatech Pharmacogenetics</td><td>RT801</td><td>Instrument required for DNA extraction</td></tr><tr><td>Vortex e.g. EasyPGX centrifuge/vortex 1.5 ml&amp;nbsp;</td><td>Diatech Pharmacogenetics</td><td>RT802</td><td>Instrument required for DNA extraction</td></tr></tbody></table>

evaluation of colorectal cancer risk and prevalence by stool dna integrity detection

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Nowadays, stool DNA can be isolated and analyzed by several methods. The long fragments of DNA in stool can be detected by a qPCR assay, which provides a reliable probability of the presence of pre-neoplastic or neoplastic colorectal lesions. This method, called fluorescence long DNA (FL-DNA), is a fast, non-invasive procedure that is an improvement upon the primary prevention system. This method is based on evaluation of fecal DNA integrity by quantitative amplification of specific targets of genomic DNA. In particular, the evaluation of DNA fragments longer than 200 bp allows for detection of patients with colorectal lesions with very high specificity. However, this system and all currently available stool DNA tests present some general issues that need to be addressed (e.g., the frequency at which tests should be carried out and optimal number of stool samples collected at each timepoint for each individual). However, the main advantage of FL-DNA is the possibility to use it in association with a test currently used in the CRC screening program, known as the immunochemical-based fecal occult blood test (iFOBT). Indeed, both tests can be performed on the same sample, reducing costs and achieving a better prediction of the eventual presence of colorectal lesions.

The workflow of this protocol is shown in Figure 1. The workflow provides two control steps and different actions according to these step results. First, if a sample presents unsuitable controls, the amplification must be repeated. Second, if the amplification is inhibited, the sample must be reprocessed from the beginning or classified as not valuable.
Figure 2 shows the fluorescence curves produced by positive and negative samples. (A) Shown...

The presented diagnostic FL-DNA kit is a time-saving and user-friendly method to determine the reliable probability of the presence of colorectal cancer lesions.

Nowadays, stool DNA can be isolated and analyzed by several methods. The long fragments of DNA in stool can be detected by a qPCR assay, which provides a ...

evaluation-colorectal-cancer-risk-prevalence-stool-dna-integrity

Research

JoVE Journal

Cancer Research

Reduced/absent expression of Pms2 and/or ERCC1 in entire crypts is a frequent event within 10 cm on each side of colonic adenocarcinomas, likely the basis of a field defect with high mutability and progression to cancer. Deficiency in Ku86 or CcOI is much less frequent in these field defects.

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

We described a procedure for the disaggregation of colorectal cancer (CRC) to produce viable single cells, which are then captured on customized antibody microarrays recognizing surface antigens (DotScan CRC microarray).  Sub-populations of cells bound to the microarray can be profiled by fluorescence multiplexing using monoclonal antibodies tagged with fluorescent dyes.

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing

This video describes DNA isolation protocol from stool samples of colon tumor-bearing mice. The extracted DNA is amplified using PCR, and the product is further cleaned using a magnetic beads-based approach. This method can be used to determine the effect of environmental enrichment on colon microbiota and animal mortality.

Stool Microbial DNA Isolation: Studying the Effect of Environmental Enrichment on Microbiome Diversity in Murine Tumor Model

We report significant improvements for the reproducible measurement of somatic colonic stem cell mutations after exposure of mice to potential DNA damaging agents.

Quantification of  Colonic Stem Cell Mutations

A method for analyzing DNA integrity in the cell-free supernatant fraction of urine samples is proposed. The method is suitable for early detection of urological malignancies and has proven accurate for the early diagnosis of bladder cancer.

Cell-Free DNA Integrity Analysis in Urine Samples

Environmental Enrichment (EE) is an animal housing environment that is used to reveal mechanisms that underlie the connections between lifestyle, stress, and disease. This protocol describes a procedure that uses a mouse model of colon tumorigenesis and EE to specifically define alterations in microbiota biodiversity that may impact animal mortality.

A Method to Define the Effects of Environmental Enrichment on Colon Microbiome Biodiversity in a Mouse Colon Tumor Model

Digital polymerase chain reaction (PCR) is a useful tool for the high-sensitivity detection of single nucleotide variants and DNA copy number variants. Here, we demonstrate key considerations for measuring rare variants in the human genome using digital PCR with the chip-in-a-tube format.

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format

Presented here is a protocol to discover the overexpressed driver genes maintaining the established cancer stem-like cells derived from colorectal HT29 cells. RNAseq with available bioinformatics was performed to investigate and screen gene expression networks for elucidating a potential mechanism involved in the survival of targeted tumor cells.

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

We present a flexible protocol for generating high-quality viral size fraction metagenomes (viromes) from human stool samples. Originally developed for soil viromics, here this protocol was successfully applied to stool samples, enabling robust characterization of the human gut virosphere.

DNA Viral Size Fraction Metagenomics for Human Stool Samples

We describe the establishment of orthotopic colorectal tumors via injection of tumor cells or organoids into the cecum of mice and the subsequent isolation of circulating tumor cells (CTCs) from this model.

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Learn a non-invasive stool DNA method to detect colorectal neoplastic lesions using the FL-DNA kit with qPCR analysis. This approach enhances screening accuracy when combined with existing tests for better patient outcomes.

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Explore More Videos